CJC-1295 Without DAC is a synthetic analogue of growth hormone-releasing hormone (GHRH). Distinct from the DAC conjugated variant, this version excludes the drug affinity complex modification, which removes the albumin-binding property and results in a relatively shorter biological half-life. This characteristic grants researchers more flexible and controllable dosing schemes during trials, making it ideal for studies requiring precise timing of peptide exposure.

This peptide works by binding to GHRH receptors on pituitary somatotroph cells to stimulate endogenous growth hormone release. Unlike many peptides that directly mimic growth hormone, CJC-1295 Without DAC triggers physiological GH secretion rather than constant exogenous supply, helping scientists investigate pituitary endocrine regulation and related downstream signaling cascades. It is widely adopted in cell culture and animal research models focusing on endocrine function, body composition and hormone secretion rhythm.

Our CJC-1295 Without DAC is synthesized by solid-phase peptide synthesis and purified via multi-step preparative chromatography. As a long linear peptide, incomplete amino acid coupling is a primary impurity risk in production. Each batch is subjected to mass spectrometry validation to confirm the integrity of the full sequence. HPLC testing monitors impurity levels to guarantee stable batch-to-batch consistency. Lyophilization effectively locks bioactivity and protects the peptide from degradation during shipment and cold storage.

After reconstitution, the peptide solution is vulnerable to protease cleavage and thermal degradation. It is strongly recommended to separate the reconstituted solution into single-use aliquots immediately. Repeated freeze-thaw cycles will break the peptide chain and reduce biological activity. Operators must wear standard lab protective gear during weighing and solution preparation to prevent contamination.